Wednesday, March 09, 2011
Safety Interaction Trial for Ibudilast and Methamphetamine
Ibudilast is an exciting medication candidate for treating methamphetamine dependence. When individuals become abstinent from methamphetamine during early recovery, the body starts an inflammatory process in neurons, especially glial cells. Glial cells are important in that they provide support to the nerve cells that are involved in thought, movement, and other human activities. By dampening inflammation in glial cells, ibudilast may preserve glial and other nerve cells during early abstinence, which in turn may help individuals feel better and think better during treatment.
Read more about our safety interaction trial for ibudilast and methamphetamine at ClinicalTrials.gov.
Tags: clinical trial, crystal meth users, harbor-ucla, ibudilast, methamphetamine, safety, ucla
Posted by UCLA SARx at 2:03 PM